Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aversa

Showing results (1201-1210 of 1,227) with videos related to

Pageof 123
Sort By:
Journal of Endocrinological Investigation|May 22, 2019
Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE)M Caprio, M Infante, E Moriconi, et al.
Frontiers in Pediatrics|May 29, 2019
Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB StudyLuca Filippi, Giacomo Cavallaro, Elettra Berti, et al.
Frontiers in Immunology|November 2, 2023
Mucosal immune alterations at the early onset of tissue destruction in chronic obstructive pulmonary diseaseCharlotte de Fays, Vincent Geudens, Iwein Gyselinck, et al.
European Urology|May 1, 2019
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate CancerAdam Sharp, Jon C Welti, Maryou B K Lambros, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
Genes and Immunity|August 26, 2011
The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphomaA Carvalho, C Cunha, A J Almeida, et al.
Seminars in Hematology|December 4, 2018
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study<sup>⁎</sup>Francesca Palandri, Giuseppe A Palumbo, Alessandra Iurlo, et al.
Haematologica|September 21, 2019
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMTBhagirathbhai Dholaria, Bipin N Savani, Myriam Labopin, et al.
Cancer Research|November 10, 2021
HER3 Is an Actionable Target in Advanced Prostate CancerVeronica Gil, Susana Miranda, Ruth Riisnaes, et al.
European Urology|November 12, 2020
Advanced Prostate Cancer with ATM Loss: PARP and ATR InhibitorsAntje Neeb, Nicolás Herranz, Sara Arce-Gallego, et al.
Pageof 123

Showing results (1201-1210 of 1,227) with videos related to

Sort By:
Pageof 123
Journal of Endocrinological Investigation|May 22, 2019
Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE)M Caprio, M Infante, E Moriconi, et al.
Frontiers in Pediatrics|May 29, 2019
Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB StudyLuca Filippi, Giacomo Cavallaro, Elettra Berti, et al.
Frontiers in Immunology|November 2, 2023
Mucosal immune alterations at the early onset of tissue destruction in chronic obstructive pulmonary diseaseCharlotte de Fays, Vincent Geudens, Iwein Gyselinck, et al.
European Urology|May 1, 2019
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate CancerAdam Sharp, Jon C Welti, Maryou B K Lambros, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
Genes and Immunity|August 26, 2011
The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphomaA Carvalho, C Cunha, A J Almeida, et al.
Seminars in Hematology|December 4, 2018
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study<sup>⁎</sup>Francesca Palandri, Giuseppe A Palumbo, Alessandra Iurlo, et al.
Haematologica|September 21, 2019
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMTBhagirathbhai Dholaria, Bipin N Savani, Myriam Labopin, et al.
Cancer Research|November 10, 2021
HER3 Is an Actionable Target in Advanced Prostate CancerVeronica Gil, Susana Miranda, Ruth Riisnaes, et al.
European Urology|November 12, 2020
Advanced Prostate Cancer with ATM Loss: PARP and ATR InhibitorsAntje Neeb, Nicolás Herranz, Sara Arce-Gallego, et al.
Pageof 123